The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
EYE ON CHINA
to-BBB and Sihuan enter into collaboration agreement

To-BBB, a brain drug development company, is entering into a collaboration agreement with Sun Moral International (HK) Limited, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Limited. The agreement aims at the collaborative research and development of innovative drugs for Central Nervous System (CNS) diseases.

to-BBB and Sihuan will conduct feasibility studies by applying to-BBB's G-Technology®, a patented brain drug delivery technology for sustained release and enhanced brain delivery, to certain drug compounds owned by Sihuan. Based on the successful completion of the feasibility studies, both parties desire to enter into a commercial license agreement for collaborative development of one or more drug compounds using to-BBB's G-Technology.

Sihuan shall pursue the approval of the developed products in China. "Sihuan entered into the collaboration agreement with the aim to tap the high unmet medical need of drug products with sustained delivery to the CNS," says Dr. Che FengSheng, CEO and Chairman of Sihuan. "The collaboration will combine the research efforts of to-BBB's brain targeting technology and Sihuan's R&D resources in oncology and CNS. The R&D program will be overseen by a joint steering committee with representatives from to-BBB and Sihuan. The two parties will share the achievements of the R&D project."

"We are pleased by Sihuan's recognition that the G-Technology offers the safest possibility to enhance the delivery of drugs across the blood-brain barrier, aiming at therapeutic approaches for treating devastating CNS diseases," says Dr. Pieter Gaillard, CSO of to-BBB. "This unique approach has obtained multiple pre-clinical and clinical validations, including the development of to-BBB's lead product 2B3-101 for brain cancer that is currently in a Phase IIa trial."

Click here for the complete issue.